



Anticancer activity profiling of parthenolide analogs generated via P450-mediated chemoenzymatic synthesis



Hanan Alwaseem^a, Benjamin J. Frisch^b, Rudi Fasan^{a,*}

^a Department of Chemistry, University of Rochester, Rochester, NY 14627, United States

^b Department of Medicine Hematology/Oncology Division, School of Medicine and Dentistry, University of Rochester, Rochester, NY 14627, United States

ARTICLE INFO

Article history:

Received 1 May 2017

Revised 31 July 2017

Accepted 7 August 2017

Available online 8 August 2017

Keywords:

Parthenolide

Sesquiterpene lactones

Anticancer activity

Chemoenzymatic synthesis

Cytochrome P450_{BM3}

Enzymatic hydroxylation

Late-stage C–H functionalization

ABSTRACT

The plant-derived sesquiterpene lactone parthenolide (PTL) was recently found to possess promising anticancer activity but elaboration of this natural product scaffold for optimization of its pharmacological properties has proven challenging via available chemical methods. In this work, P450-catalyzed C–H hydroxylation of positions C9 and C14 in PTL was coupled to carbamoylation chemistry to yield a panel of novel carbamate-based PTL analogs ('parthenologs'). These compounds, along with a series of other C9- and C14-functionalized parthenologs obtained via O–H acylation, alkylation, and metal-catalyzed carbene insertion, were profiled for their cytotoxicity against a diverse panel of human cancer cell lines. These studies led to the discovery of several parthenologs with significantly improved anticancer activity (2–14-fold) compared to the parent molecule. Most interestingly, two PTL analogs with high cytotoxicity (LC₅₀ ~ 1–3 μM) against T cell leukemia (Jurkat), mantle cell lymphoma (JeKo-1), and adenocarcinoma (HeLa) cells as well as a carbamate derivative with potent activity (LC₅₀ = 0.6 μM) against neuroblastoma cells (SK-N-MC) were obtained. In addition, these analyses resulted in the identification of parthenologs featuring both a broad spectrum and tumor cell-specific anticancer activity profile, thus providing valuable probes for the future investigation of biomolecular targets that can affect cell viability across multiple as well as specific types of human cancers. Altogether, these results highlight the potential of P450-mediated chemoenzymatic C–H functionalization toward tuning and improving the anticancer activity of the natural product parthenolide.

© 2017 Elsevier Ltd. All rights reserved.

1. Introduction

Sesquiterpene lactones (SQLs) are a class of plant-derived natural products exhibiting a broad spectrum of biological activities including anti-inflammatory, anti-viral and anti-proliferative properties.^{1,2} These bioactive compounds commonly share an α -methylene- γ -lactone ring which is critical for their biological activity.^{2,3} Parthenolide (PTL), a SQL isolated from various plants in the *Asteraceae* family, has attracted significant attention owing to its promising activity as an antileukemic agent. PTL was indeed shown to induce apoptosis in human acute myelogenous

leukemia (AML) cells as well as in AML stem cell subpopulations while sparing normal cells.^{3–5} Beside AML, PTL was found to possess cytotoxic activity against a variety of other human cancer cells.^{6–12} The anticancer activity of PTL involves a complex mechanism of action as a result of the ability of this compound to target and affect a broad range of cellular processes. These cellular processes primarily include inhibition of the NF- κ B transcription factor complex,^{4,13,14} activation of the p53 pathway¹⁵ and generation of reactive oxygen species (ROS)^{4,16} and associated oxidative stress in cancer cells. Other studies have linked the anticancer activity of PTL to inhibition of the STAT3 transcription factor,¹⁷ activation of proapoptotic proteins,¹⁸ and epigenetic modulation (NSD1, SETD2, HDAC1).^{15,19,20}

Owing to the promising activity of PTL as an antileukemic and anticancer agent, there has been a growing interest in modifying the PTL scaffold with the goal of improving its cytotoxicity and selectivity against cancer cells. By chemical means, functionalization of PTL structure has involved modification of the reactive C13 position (via Michael addition of amine nucleophiles^{21–24} or Heck

Abbreviations: PTL, parthenolide; AML, acute myelogenous leukemia; CSCs, cancer stem cells; DMAPT, dimethylamino-parthenolide; PTDH, phosphite dehydrogenase; NADPH, nicotinamide adenine dinucleotide phosphate (reduced); IPTG, β -D-1-thiogalactopyranoside; δ -ALA, δ -aminolevulinic acid; TB, terrific broth; DMSO, dimethylsulfoxide; DBTDL, dibutyltin laurate.

* Corresponding author.

E-mail address: rfasan@ur.rochester.edu (R. Fasan).

coupling²²) and of the C1-10 double bond⁹ (via cyclopropanation). These modifications have resulted in semi-synthetic PTL analogs with comparable or reduced anticancer activity compared to the parent natural product. Functionalization of the C13 position, in particular, has often led to a decrease or loss of anticancer activity, likely due to the critical importance of the α -methylene- γ -lactone ring for biological activity. As an exception, C13-dimethylamino-parthenolide (DMAPT) was found to maintain PTL-like antileukemic activity while exhibiting improved oral bioavailability, thus enabling an initial assessment of PTL therapeutic potential in animal models of AML.^{21,24} Subsequent studies suggested that DMAPT may act as a prodrug that releases PTL in the presence of glutathione.²⁵

In the interest of expanding opportunities for manipulation of the PTL scaffold, our group has recently engineered variants of the bacterial fatty acid P450 monooxygenase CYP102A1 (P450_{BM3}) that are capable of hydroxylating positions C9 and C14 in PTL with high regio- and stereoselectivity.²⁶ The corresponding hydroxylated derivatives could be further elaborated via acylation or alkylation resulting in the identification of PTL analogs (referred to herein also as “parthenologs”) with enhanced cytotoxic activity and selectivity against AML cells and patient-derived primary AML specimens.^{26,27} In the present work, we first extended the scope of this chemoenzymatic approach to PTL functionalization by coupling P450-catalyzed hydroxylation with carbamoylation to yield a panel of carbamate-based parthenologs. Compared to the ester linkage in the acylated PTL analogs, the carbamate linkage provides superior hydrolytic stability while serving as both a H-bond donor and H-bond acceptor.^{28,29} Because of these properties, carbamate functionalities have found widespread use in medicinal chemistry and they are integral part of a number of marketed drugs (Fig. 1).^{30–33}

The anticancer activity of C9- and C14-functionalized parthenologs has so far been investigated only in context of AML. Here, we report the profiling of the anticancer activity of a large panel of C9- and C14-modified parthenologs, including the newly available carbamate derivatives, across a diverse spectrum of human cancer cell lines including those derived from T cell leukemia, lymphoma, and different types of solid tumors. Our results show that functionalization of the C9/C14 positions can dramatically alter the anticancer activity profile of this molecule, resulting in parthenologs that feature both a broad spectrum as well as cancer cell-specific cytotoxicity. In addition, these studies led to the discovery of PTL analogs with potent activity against T cell leukemia, mantle cell lymphoma, and neuroblastoma cells.

2. Results and discussion

2.1. Optimized protocol for synthesis of C9 and C14 oxyfunctionalized PTL analogs

We recently reported the development and application of engineered variants of CYP102A1 from *Bacillus megaterium* for the selective hydroxylation of position C9 and C14 in PTL.^{26,34} The products of these enzymatic reactions, namely 9(S)-hydroxy-PTL (**2**) and C14-hydroxy-PTL (**3**), can serve as valuable intermediates for the generation of C9- and C14-functionalized PTL analogs via chemical modification of the enzymatically installed hydroxyl group. Previously, **2** and **3** were prepared using CYP102A1 variants II-C5 and FL#46, respectively, in the presence of a NADPH cofactor regeneration system consisting of a thermostable phosphite dehydrogenase (PTDH),^{35,36} NADP⁺ and sodium phosphite as the sacrificial hydride donor. The enzymatic transformation could be carried using lysate of the P450-expressing *E. coli* cells directly, which bypasses the need for purification of the P450 enzyme.²⁷ Attempts to further streamline the process by using a two-plasmid system for co-expression of both the P450 and PTDH in the host cells resulted however in reduced product conversion and isolated yield for both **2** and **3**.²⁷

To investigate the basis of this phenomenon, we conducted experiments in which either P450 or PTDH was supplemented at varying concentration (0.5–1 μ M) to the lysate of *E. coli* cells co-expressing the P450 and PTDH enzymes. Insightfully, the hydroxylation reactions with P450-supplemented lysate did not show any improvement in PTL conversion to **2** (or **3**), whereas those carried out with PTDH-supplemented lysate were found to reproduce the results obtained using our reference conditions (i.e., P450-expressing cell lysate with exogenously added PTDH at 2 μ M). These results clearly indicated that the performance of the co-expression system is limited by the expression levels of PTDH. These conclusions were corroborated by additional experiments in which cells were induced with variable amounts of L-arabinose, which controls the transcription of the PTDH gene, and IPTG, which controls the transcription of the P450 gene. Specifically, a 2-fold increase in the L-arabinose concentration during induction (0.12% m/v), in combination with 0.5 mM IPTG (for P450 expression) and 0.3 mM (δ -aminolevulinic acid for heme biosynthesis), was found to result in adequate and reproducible levels of P450 and PTDH after cell lysis. Using the lysate of 1 L cell cultures prepared under these conditions, 0.1 g of PTL could be fully transformed resulting in the isolation of **2** and **3** in 44% and 54% yield, respectively (Scheme 1). By completely eliminating the need for purification of the enzymes required for both the hydroxylation reaction and NADPH cofactor regeneration, this procedure provides an improved and streamlined approach to the synthesis of these compounds for further functionalization.

2.2. Synthesis of PTL analogs via carbamoylation and other chemistries

Previously, we found that the installation of aromatic substituents at either the C9 or C14 position of PTL were most effective toward improving the antileukemic activity of this natural product.²⁶ Building upon these findings, we designed and targeted the synthesis of a panel of carbamate PTL analogs that bears varying substituted aryl groups at those positions. To afford these compounds, we were attracted by the mild reaction conditions provided by the carbamoylation of primary and secondary alcohols with isocyanates in the presence of tin-based catalyst.^{37,38} In particular, this reaction proceeds under neutral conditions, which was deemed important in view of the relative instability of the PTL scaffold under acidic or basic conditions. Gratifyingly, the desired carbamate-based parthenologs could be successfully prepared starting from **2** or **3** in the presence of the appropriate






Fig. 1. Marketed drugs containing carbamate moieties.




Scheme 1. Chemoenzymatic synthesis of C9- and C14-functionalized PTL analogs via P450-catalyzed hydroxylation and carbamoylation chemistry. (a–b) 1 mM parthenolide, cell lysate containing ~0.1 mol% P450 and ~2 μ M PTDH, 150 μ M NADP⁺, 50 mM sodium phosphite in 50 mM potassium phosphate buffer (pH 8.0), room temperature, 14 h. P450 variant II-C5 was used for (a), and P450 variant FL#46 for (b); (c) R–NCO, DBTDL, DCM, room temperature (3–12 h).

isocyanate reagent and catalytic amounts of dibutyltin dilaurate (DBTDL) (Scheme 1). The optimized protocol for these transformations involved dissolving the hydroxylated PTL precursor in dry dichloromethane followed by addition of the isocyanate reagent (1.4 equiv) and 20 mol% DBTDL. In general, faster reaction kinetics (3–4 h) were observed for functionalization of **3** vs. **2**, which bears a more sterically hindered, secondary alcohol, or in the presence of electronically activated isocyanates (e.g., *p*-nitrophenyl isocyanate to give **12–13**). More extended reaction times (12–15 h) and excess isocyanate (4 equiv.) were required for functionalization of **2** in the presence of more sterically reagents such as 1-isocyanatonaphthalene (to give **11**). In any case, both the C9- and C14-functionalized PTL derivatives could be prepared and isolated in good to excellent yields (35–90%; Scheme 1).

In addition to **4–13**, a series of C9- and C14-functionalized parthenologs were prepared via acylation, alkylation, or metal-catalyzed carbene O–H insertion of **2** and **3**, respectively, according to our previously reported protocols (Scheme 2).^{26,27} These compounds were selected from among those exhibiting most promising activity against AML cells (LC_{50} = 2–10 μ M).^{26,27} In addition, these analogs were chosen to provide a range of different functionalization patterns and linkages (i.e., ester or ether linkage) at the C9 and C14 position, in order to examine the effect of these structural features on their anticancer activity.

2.3. Anticancer activity profiling of PTL analogs

In addition to antileukemic activity, PTL has been reported to display promising cytotoxicity against other human cancers,



Scheme 2. Synthesis of C9- and C14-functionalized PTL analogs via acylation, alkylation and O–H carbene insertion chemistry.

including breast,^{39,40} prostate,⁴¹ and pancreatic⁴² cancer. Whereas our previous studies demonstrated the beneficial effect of functionalization at the C9 or C14 sites for improving PTL cytotoxicity against AML cells, the potential of these structural modifications toward modulating and improving its activity against other forms of human cancer was not assessed.

To this end, the parthenologs described in Schemes 1 and 2 were screened for their activity against a broad panel of cancer cell lines, including HeLa (cervical cancer), MDA-MB-231 (breast), SK-N-MC (neuroblastoma), SK-MEL-2 (melanoma), SJS-1 (osteosarcoma), A549 (lung cancer), HCT-116 (colon cancer), PC-3 (prostate cancer), Jurkat (acute T cell leukemia) and JeKo-1 (B cell lymphoma) cells. Cell viability was determined by a standard colorimetric assay using a tetrazolium dye, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) which correlates metabolic activity with cell viability. Using this assay, PTL was determined to exhibit a half-maximal lethality dose (LD_{50}) between 10 and 45 μ M, depending on the cell line (Table 1). Accordingly, an initial screening of the in vitro anticancer activity of the PTL analogs was carried out at a fixed concentration of 10 μ M.

From these experiments, a heat map was generated to highlight compounds showing high (70–100% cell death, red), moderate (40–60% cell death, white to light red/blue) and low (0–30% cell death, blue) cytotoxicity against the various cancer cell lines (Fig. 2). As shown by the plot, the hydroxylated parthenolide derivatives **2** and **3** show low or no cytotoxicity (0–10% cell death) against all of the cell lines, with the exception of the HeLa cells. In contrast,




Fig. 2. Cytotoxicity of PTL and of the parthenologs against the panel of cancer cell lines at the standard dose of 10 μ M (n = 5). Standard deviation is within 10%. Reported values corresponds to: (% cell viability)/100. See Table S1 for complete data and for cytotoxicity data against Jurkat and JeKo-1 cells at the lower compound dose (2 μ M).

many of the parthenologs were determined to possess enhanced anticancer activity compared to PTL. Notably, most of the analogs (>85%) were found to exhibit high cytotoxicity against acute T cell

leukemia (Jurkat) and B cell lymphoma cells (JeKo-1), causing >80–100% cell death at 10 μ M. These results clearly indicate that the beneficial effect of C9 and C14 substitutions are not restricted to improving PTL activity against AML cells^{26,27} but extend to other forms of leukemia (Jurkat) and to lymphoma (JeKo-1). To further discriminate the most potent analogs against these two cancer cell lines, the cytotoxicity assay was repeated at a 5-fold lower compound dose (i.e., 2 μ M). Under these conditions, the most promising analogs (>20–40% reduction in cell viability) were identified as the carbamate analogs **6–9** and ester derivatives **17–19** (Table S1).

Compared to the blood cancer cell lines, a rather different scenario emerged from profiling of the compounds' activity against cell lines derived from solid tumors. In this case, a relatively smaller albeit still sizeable fraction of the analogs (~30%) were found to display improved cytotoxicity activity compared to PTL (i.e., >2-fold reduction in % cell viability) toward one or more cancer cell lines. Interestingly, the majority of the improved analogs corresponds to either carbamate or ester derivatives (Fig. 2). In comparison, only one compound out of the eight ether-based analogs (**32**) showed noticeably improved anticancer activity compared to PTL. Since some of these analogs share a structurally related or even identical aryl group at the same functionalization site (e.g., **29** and **33** vs. **15**), these results point at the critical importance of the ester/carbamate linkage for anticancer activity in the context of solid tumors. This is in contrast to the high activity exhibited by many of the ether-based PTL analogs against leukemia and lymphoma cells as determined here (Fig. 2) and previously²⁷ for AML cells.

Other interesting trends emerged from a more in-depth analysis of structure-activity data relative to the carbamate- and ester-based parthenologs. Within the carbamate group, an increase in cytotoxicity against multiple cancer cell lines is observed upon installation of fluoro- and trifluoromethyl-substituted phenyl groups at either functionalization site (C9 or C14) of the PTL scaffold (i.e., **8–9** > **6–7** > **4–5**). A similar trend is observed across the ester series of PTL analogs (i.e., **16–19** > **14–15**). These results indicate that an increase in lipophilicity in the appended aryl group is generally beneficial toward enhancing the anticancer activity of these compounds. At the same time, a marked dependence of such activity on the size of the aryl group is also evident, as indicated by the moderate activity of **10**, **11**, **20**, and **21**, which carry a naphthyl substituent at position C9/C14.

Particularly interesting is the effect of the C9/C14 functionalizations on the overall spectrum of anticancer activity exhibited by the parthenologs, especially in the context of the solid tumor cell lines. In this regard, two general activity profiles can be recognized from the data in Fig. 2, corresponding to compounds showing either a broad spectrum or a cancer cell-selective activity profile. Relevant representatives of the first group are the fluorinated PTL analogs **9**, **16**, **17** and **19**, which show high cytotoxicity (>70–80% reduction in cell viability) against most if not all of the cancer cell lines tested. Belonging to this group is also the carbamate analog **13** and the pyrazole-containing analog **27**. Interestingly, the broad anticancer activity profile of the latter appears to be directly linked to the presence of the pyrazole ring, as structurally related analogs such as **23** and **26** fail to present such behavior. The pyrazole group is a well known privileged scaffold in medicinal chemistry due to its ability to mediate interactions with proteins via hydrogen bonding (donor/acceptor), π - π interactions and cation- π interactions.^{43,44}

In contrast to the compounds mentioned above, a subset of the parthenologs was found to feature tumor type selectivity, exhibiting high activity against only a few or even just one of the solid cancer cell lines. Among these, compounds **8** and **18**, which share a (3,5-bis-trifluoromethyl)phenyl substituent at position C9, show high cytotoxicity (>80% reduction in cell viability) against

Table 1
Cytotoxicity of PTL and selected parthenologs against various cell lines. LC₅₀ values are mean ± SD (n = 6).

Compound	Jurkat (blood)	JeKo-1 (blood)	HeLa (cervix)	A549 (lung)	HCT-116 (colon)	SJSA-1 (bone)	SK-N-MC (brain)	PC-3 (prostate)	MDA-MB-231 (breast)	SK-MEL-2 (skin)
PTL	16.9 ± 3.0	10.0 ± 1.1	9.0 ± 0.8	29.7 ± 1.7	18.0 ± 1.7	42.4 ± 3.9	4.7 ± 0.8	20.5 ± 1.3	18.3 ± 1.1	24.9 ± 3.8
6 (9–32)	–	–	–	–	11.8 ± 2.7	–	–	–	–	–
7 (14–32)	–	6.7 ± 0.5	–	–	–	–	–	–	–	–
8 (9–33)	2.8 ± 0.2	3.5 ± 0.3	–	–	7.9 ± 0.3	–	–	–	7.2 ± 0.7	–
9 (14–33)	3.3 ± 0.2	3.4 ± 0.4	1.5 ± 0.1	5.5 ± 0.4	5.9 ± 0.2	9.2 ± 0.0	0.6 ± 0.2	5.5 ± 0.2	6.1 ± 0.6	4.3 ± 0.9
13 (14–35)	–	–	1.7 ± 0.1	–	7.8 ± 0.4	–	–	5.7 ± 0.2	–	–
16 (9–12)	–	–	2.1 ± 0.1	–	–	–	5.7 ± 0.2	5.3 ± 0.2	5.7 ± 0.9	–
17 (14–12)	–	–	2.9 ± 0.1	–	8.2 ± 0.6	7.7 ± 0.6	5.6 ± 0.2	6.7 ± 0.5	–	–
18 (9–13)	1.2 ± 0.1	1.2 ± 0.1	–	–	–	–	4.7 ± 0.5	3.1 ± 0.2	3.8 ± 0.4	2.6 ± 0.2
19 (14–13)	1.9 ± 0.1	1.7 ± 0.2	1.5 ± 0.1	4.9 ± 0.2	5.7 ± 0.2	6.4 ± 0.8	0.6 ± 0.2	4.7 ± 0.4	6.2 ± 0.7	–
24 (14–18)	–	–	–	–	11.8 ± 1.6	–	–	–	–	–
25 (9–19)	–	–	–	–	8.3 ± 0.3	–	–	–	–	–
27 (14–20)	2.3 ± 0.3	–	1.7 ± 0.1	–	7.1 ± 0.3	6.7 ± 0.5	–	–	–	–

breast, prostate, cervical, and brain cancer cells, but moderate or low cytotoxicity (<30–50% reduction in cell viability) against lung, bone, and skin cancer cells. Of note, **8** is more active than **18** against colon cancer cells (HCT-116) but less active against skin cancer cells, which also highlights the functional importance of the carbamate vs. ester linkage for the observed biological activity. Interestingly, the colon cancer cell line HCT-116 was uniquely sensitive, compared to the other types of solid cancers, to the carbamate analog **6** or to the ester derivatives **23**, **24**, and **25**. The latter compounds share a heterocycle-containing biaryl group, which thus represents a key structural motif for enhancing the anticancer activity of PTL in colon cancer cells. Noteworthy is also the activity profile of the carbamate analog **11**, which shows high cytotoxicity only against B cell lymphoma cells within the entire panel of cancer cell lines tested (Fig. 2).

Valuable structure-activity insights emerged also from comparison of the data relative to PTL analogs carrying an identical substitution at the C9 vs. C14 position. Whereas regioisomeric ‘pairs’ such as **6/7**, **14/15**, and **16/17** share a very similar anticancer activity profile, a distinctive impact of the site of functionalization on anticancer activity is apparent for others, including **8/9**, **12/13**, **18/19**, **25/26** and **32/33**. Particularly striking is the case of the carbamate analogs **12** and **13**, for which functionalization of the C14 site results in a broad spectrum anticancer activity (**13**), whereas the same substitution at position C9 leads to enhanced cytotoxicity only against colon cancer (HCT-116) and blood cancer cells (Jurkat, JeKo-1). Also notable is the high selectivity of the C14-functionalized **11** against lymphoma cells when compared to the C9-substituted counterpart **10**. In other cases, modification of the C9 vs. C14 position is critical for the observed anticancer activity, as shown by significantly higher cytotoxicity of **25** and **32** (compared to **26** and **33**, respectively) against colon cancer cells.

2.4. LC₅₀ determination

Based on the data summarized in Fig. 2, the most promising PTL analogs were selected for more quantitative analysis of their anticancer activity via dose-response curves. Selection criteria were a ≥80% reduction in cell viability for any of solid cancer cell lines after incubation with the compound at the standard 10 μM concentration, and/or ≥25% reduction in viability of leukemia (Jurkat) or lymphoma cells (JeKo-1) at the reduced compound dose of 2 μM. Half-maximal lethal concentration (LC₅₀) values were obtained from dose-dependent cell viability curves after normalization to control cells treated with vehicle only (media with 1% DMSO).

As summarized in Table 1, the different cancer cell lines show a variable degree of sensitivity to PTL, with SK-N-MC, JeKo-1, and HeLa cells showing LC₅₀ values between 4.7 and 10.0 μM and

A459 and SJSA-1 cells being about 5-fold less sensitive to this compound (LC₅₀ = 29.7–42.4 μM). Consistent with the results from the initial activity profiling, the LC₅₀ values corresponding to the tested PTL analogs demonstrate a significant increase in anticancer activity compared to PTL (Fig. 2). The largest activity enhancement is exhibited by **18** against Jurkat cells, which corresponds to a 14-fold decrease in LC₅₀ (1.2 μM vs. 16.9 μM for PTL). In general, the analogs containing trifluoromethyl-substituted aryl rings (**9**, **17**, **18**, **19**) emerged as the most active compounds, displaying low micromolar to submicromolar LC₅₀ values across all of the cancer cell lines tested. Within this subset of parthenologs, the impact of the functionalization chemistry (carbamoylation vs. esterification) on the compound anticancer properties are evident from comparison of **8** vs. **18** and **9** vs. **19**. While these compounds share very similar LC₅₀ values against cancer cells derived from solid tumors, **18** and **19** show a twofold higher cytotoxicity compared **8** and **9**, respectively, against Jurkat and JeKo-1 cells. Comparison of the activity data relative to **16** vs. **18** and to **17** vs. **19** revealed the functional implications of subtle structural variations in the appended aryl group (i.e., *meta,meta*- vs. *ortho,para* bis-trifluoromethylation). Particularly notable in this case is the higher activity (2- to 3-fold lower LC₅₀) of **19** vs. **17** against HeLa cells, and of **18** vs. **16** against breast (MDA-MB-231) and prostate (PC-3) cancer cells.

As it became evident from the data of Fig. 2, the functionalization site (C9 vs. C14) has a variable effect on the anticancer activity of the compounds, depending on the nature of the substituent and on the type of cancer cell. For example, **16** and **17** are equally active against HeLa, SK-N-MC, and PC-3 cells. In contrast, important differences in anticancer activity are observed for the C9-functionalized analogs **8** and **18** when compared to their C14-functionalized counterparts, **9** and **19**, respectively. For example, **19** displays a >2–4-fold lower LC₅₀ than **18** (1.5–6.4 vs. >10 μM) against epithelial (HeLa), lung (A459), colon (HCT-116), and bone (SJSA-1) cancer cells, whereas **18** exhibits higher (ca. two-fold) cytotoxicity than **19** against prostate (PC-3) and breast (MDA-MB-231) cancer cells. To gain further insights into this aspect, the three-dimensional structure of a representative C9-functionalized analog (**14**) was determined by X-ray crystallography (Fig. 3). These analyses show how functionalization of the pro-(S) C–H bond in C9 places the appended aryl group in the same region of the C14 methyl group. Accordingly, C9- and C14-functionalized analogs are expected to feature subtle differences with respect to the orientation of the appended functionality. Intriguingly, these structural differences are important for inducing high cytotoxicity in the context of certain cancer cells but not in others. Since PTL is known to target multiple proteins in cancer (AML) cells,⁴⁵ this phenomenon is likely to reflect how these structural variations (i.e., C9 vs. C14 functionalization) and those mentioned earlier (e.g., carbamate vs. ester linkage) affect the interaction of the parthenologs




Fig. 3. X-ray crystal structure of compound 14.

with their biomolecular targets. In this regard, particularly interesting are the results with the neuroblastoma cells. In this case, modification of the C14 position with a (3,5-bis-trifluoromethyl)phenyl group (**9** and **19**) is uniquely beneficial for potentiating PTL cytotoxicity in the context of these cancer cells, resulting in the most potent analogs ($LC_{50} = 0.6 \mu\text{M}$) identified over the course of this study.

Finally, it is worth noting how chemoenzymatic elaboration of the PTL scaffold has resulted in a parthenolog, **9**, possessing potent antiproliferative activity ($LC_{50} = 4.9\text{--}6.4 \mu\text{M}$) also against lung (A549) and osteosarcoma cells (SJS-1), which are considerably less sensitive to treatment with PTL ($LC_{50} > 30\text{--}40 \mu\text{M}$) compared to the other types of cancer cells investigated here (Table 1) and earlier (AML).^{26,27}

3. Conclusions

A series of C9- and C14-functionalized parthenologs were prepared by chemoenzymatic synthesis and evaluated for their activity against a diverse panel of cancer cells derived from blood and solid human tumors. Using this approach, PTL analogs exhibiting low micromolar activity ($LC_{50} \sim 1.2\text{--}6.4 \mu\text{M}$) against each of these different cancer cells were identified, along with parthenologs possessing high cytotoxicity against neuroblastoma cells ($LC_{50} = 0.6 \mu\text{M}$). The anticancer activity of these semisynthetic PTL derivatives correspond to up to 14-fold increase compared to the parent natural product, and extend to cancer cells that are relatively insensitive to this molecule (i.e., lung and osteosarcoma cells). Importantly, this study demonstrates how P450-mediated late-stage C–H functionalization of the PTL scaffold have proven effective not only toward potentiating the anticancer properties of this natural product, but also toward modulating the spectrum of activity across different types of cancer cells. As a result, parthenologs featuring both a broad spectrum of anticancer activity (e.g., **9**, **19**) as well as tumor-specific cytotoxicity (e.g., **6**, **11**, **25**) could be identified. The results reported here are expected to aid the development of PTL-based anticancer agents as well as provide valuable probes for investigating biomolecular targets affected by these molecules across both multiple and specific types of human

cancer. Further studies in these directions are currently ongoing in our laboratory.

4. Materials and methods

4.1. Reagents and substrates

Chemical reagents and solvents were purchased from commercial suppliers (Sigma-Aldrich, TCI, Fluka, and Codexis) and used without additional purification. PTL was purchased from A Chemtek. All dry reactions were carried out under argon in oven-dried glassware with magnetic stirring using standard gas-tight syringes, cannulae and septa. Silica gel chromatography purifications were carried out using AMD Silica Gel 60 230–400 mesh. ^1H and ^{13}C NMR spectra were measured on a Bruker DPX-500 (operating at 500 MHz for ^1H and 125 MHz for ^{13}C). Mass spectrometry data were collected via direct infusion on an Advion Expression compact mass spectrometer in ESI mode.

4.2. Protein expression and enzymatic hydroxylation

Plasmids containing the P450_{BM3} (pCWori vector) and PTDH (pEVOL vector) gene were co-transformed in *E. coli* DH5 α cells. A single colony was transferred into 5–7 ml LB medium containing 100 $\mu\text{g}/\text{ml}$ ampicillin and 25 $\mu\text{g}/\text{ml}$ chloramphenicol. The culture was incubated overnight at 37 $^\circ\text{C}$, 200 rpm and transferred into 1 L of TB media with 100 $\mu\text{g}/\text{ml}$ AMP and 25 $\mu\text{g}/\text{ml}$ CAM. The cells were grown at 37 $^\circ\text{C}$ (200 rpm) and induced with 0.5 mM IPTG, 0.12% m/v L-arabinose and 0.3 mM, δ -ALA at $OD_{600} = 0.8$. The cells were harvested after induction for 24 h at 27 $^\circ\text{C}$ (150 rpm), resuspended in 50 mM potassium phosphate buffer (pH 8.0) and stored at $-80 \text{ }^\circ\text{C}$ for up to 4 months. The frozen suspension was thawed at room temperature and lysed by sonication with the amplitude set at 50% and a pulse sequence of 1 s on and 4 s off for 12–15 min. The lysate was centrifuged at 14,000 rpm at 4 $^\circ\text{C}$ for 40 min and the clarified cellular lysate was used for the production of **2** and **3** as described previously.²⁷

4.3. General procedure for carbamoylation reactions

To a 0.5 dram vial containing **2** or **3** (4–10 mg) in anhydrous DCM (0.5 ml) was added the corresponding phenyl isocyanate (1.4 eq) and DBTDL (dibutyltin dilaurate) (20% mol). The reaction was stirred at room temperature for 4–12 h till completion. A saturated solution of NaHCO_3 was added and the aqueous phase was extracted with DCM (3 \times) in a conical vial. The collected organic layers were dried over Na_2SO_4 , concentrated in vacuo and purified by flash chromatography on silica gel (eluting mixture 20–50% EtOAc in *n*-Hexane) to obtain the desired product as a solid.

4.4. Compound characterization data

4.4.1. (3aS,5S,9aR,10aS,10bS,E)-6,9a-Dimethyl-3-methylene-2-oxo-2,3,3a,4,5,8,9,9a,10a,10b decahydroxireno[2',3':9,10]cyclodeca[1,2-b]furan-5-yl phenylcarbamate (**4**)

Standard procedure was applied using 9(S)-hydroxy-parthenolide (**2**) (8.4 mg, 0.032 mmol), DBTDL (0.006 mmol), and substituted phenyl isocyanate (0.045 mmol). Isolated PTL-09-31: 10.2 mg, 84% yield. ^1H NMR (500 MHz, CDCl_3): $\delta = 7.37\text{--}7.31$ (m, 2H), 7.28 (t, $J = 7.6$ Hz, 2H), 7.05 (t, $J = 7.6$ Hz, 1H), 6.34 (d, $J = 3.4$ Hz, 1H), 5.70 (d, $J = 3.4$ Hz, 1H), 5.51 (dd, $J = 3.4$, 11.9 Hz, 1H), 5.19 (d, $J = 10.5$ Hz, 1H), 3.84 (t, $J = 8.9$ Hz, 1H), 2.95–2.88 (m, 1H), 2.68 (d, $J = 8.5$ Hz, 1H), 2.51–2.39 (m, 1H), 2.33–2.21 (m, 2H), 2.17–2.11 (m, 1H), 2.06–1.98 (m, 1H), 1.73 (s, 3H), 1.63–1.51 (m, 1H), 1.30 (s, 3H) ppm, ^{13}C NMR (125 MHz, CDCl_3): $\delta = 168.7$,

158.7, 138.3, 133.1, 133.0, 129.2, 127.8, 123.8, 122.2, 121.0, 92.3, 81.7, 66.1, 61.4, 44.1, 36.4, 36.0, 23.8, 17.4, 11.8 ppm, MS (ESI) calculated for $C_{22}H_{25}NO_5$ $[M+Na]^+$ m/z : 406.43; found: 406.5.

4.4.2. ((3*aR*,9*aR*,10*aS*,10*bS*,*Z*)-9*a*-Methyl-3-methylene-2-oxo-2,3,3*a*,4,5,8,9,9*a*,10*a*,10*b*-decahydrooxireno[2',3':9,10]cyclodeca[1,2-*b*]furan-6-yl)methyl phenylcarbamate (**5**)

Standard procedure was applied using 14-hydroxy-parthenolide (**3**) (6 mg, 0.023 mmol), DBTDL (0.005 mmol), and substituted phenyl isocyanate (0.032 mmol). Isolated **PTL-14-31**: 7.3 mg, 84 % yield. 1H NMR (500 MHz, $CDCl_3$): δ = 7.37–7.30 (m, 2H), 7.26 (t, J = 7.4 Hz, 2H), 7.05 (t, J = 7.4 Hz, 1H), 6.30 (d, J = 3.4 Hz, 1H), 5.58 (d, J = 3.4 Hz, 1H), 5.47 (dd, J = 3.3, 12.5 Hz, 1H), 4.87 (d, J = 12.5 Hz, 1H), 4.65 (d, J = 11.7 Hz, 1H), 3.96 (t, J = 8.6 Hz, 1H), 2.81–2.71 (m, 2H), 2.67–2.61 (m, 1H), 2.57–2.46 (m, 1H), 2.34–2.23 (m, 1H), 2.21–2.09 (m, 3H), 1.83–1.71 (m, 1H), 1.25–1.22 (m, 4H) ppm, ^{13}C NMR (125 MHz, $CDCl_3$): δ = 169.0, 158.6, 139.1, 132.1, 132.0, 129.3, 128.1, 123.9, 121.6, 121.5, 82.3, 66.1, 61.2, 61.1, 47.4, 36.6, 36.3, 31.4, 23.9, 17.0 ppm, MS (ESI) calculated for $C_{22}H_{25}NO_5$ $[M+Na]^+$ m/z : 406.43; found: 406.4.

4.4.3. (3*aS*,5*S*,9*aR*,10*aS*,10*bS*,*E*)-6,9*a*-Dimethyl-3-methylene-2-oxo-2,3,3*a*,4,5,8,9,9*a*,10*a*,10*b*-decahydrooxireno[2',3':9,10]cyclodeca[1,2-*b*]furan-5-yl (2,4-difluorophenyl)carbamate (**6**)

Standard procedure was applied using 9(*S*)-hydroxy-parthenolide (**2**) (7.6 mg, 0.029 mmol), DBTDL (0.006 mmol), and substituted phenyl isocyanate (0.12 mmol). Isolated **PTL-09-32**: 10.8 mg, 90% yield. 1H NMR (500 MHz, $CDCl_3$): δ = 6.87–6.79 (m, 2H), 6.71 (s, 1H), 6.35 (d, J = 4.3 Hz, 1H), 5.69 (d, J = 3.5 Hz, 1H), 5.52 (dd, J = 3.9, 12.6 Hz, 1H), 5.19 (d, J = 11.3 Hz, 1H), 3.84 (t, J = 9.1 Hz, 1H), 2.95–2.88 (m, 1H), 2.69 (d, J = 20 Hz, 1H), 2.51–2.41 (m, 1H), 2.33–2.22 (m, 2H), 2.18–2.12 (m, 1H), 2.08–1.99 (m, 1H), 1.73 (s, 3H), 1.64–1.54 (m, 1H), 1.30 (s, 3H) ppm, ^{13}C NMR (125 MHz, $CDCl_3$): δ = 178.6, 168.7, 154.6, 138.0, 132.9, 128.0, 122.3, 122.2, 111.4, 111.2, 103.7, 82.1, 81.6, 66.0, 61.3, 44.1, 36.2, 36.0, 24.7, 17.4, 11.7 ppm, MS (ESI) calculated for $C_{22}H_{23}F_2NO_5$ $[M+Na]^+$ m/z : 442.41; found: 442.4.

4.4.4. ((3*aR*,9*aR*,10*aS*,10*bS*,*Z*)-9*a*-Methyl-3-methylene-2-oxo-2,3,3*a*,4,5,8,9,9*a*,10*a*,10*b*-decahydrooxireno[2',3':9,10]cyclodeca[1,2-*b*]furan-6-yl)methyl (2,4-difluorophenyl)carbamate (**7**)

Standard procedure was applied using 14-hydroxy-parthenolide (**3**) (5.9 mg, 0.022 mmol), DBTDL (0.004 mmol), and substituted phenyl isocyanate (0.031 mmol). Isolated **PTL-14-32**: 8 mg, 85% yield. 1H NMR (500 MHz, $CDCl_3$): δ = 6.87–6.79 (m, 2H), 6.68 (s, 1H), 6.31 (d, J = 3.4 Hz, 1H), 5.59 (d, J = 2.3 Hz, 1H), 5.50 (dd, J = 3.1, 12.8 Hz, 1H), 4.91 (d, J = 11.3 Hz, 1H), 4.62 (d, J = 13.2 Hz, 1H), 3.85–3.76 (m, 1H), 2.81–2.72 (m, 2H), 2.69–2.61 (m, 1H), 2.56–2.45 (m, 1H), 2.34–2.24 (m, 1H), 2.21–2.07 (m, 3H), 1.77–1.68 (m, 1H), 1.25–1.19 (m, 4H) ppm, ^{13}C NMR (125 MHz, $CDCl_3$): δ = 174.9, 169.0, 150.5, 138.9, 133.3, 128.1, 122.2, 121.6, 111.5, 111.3, 103.9, 82.5, 66.2, 62.0, 61.0, 47.2, 36.3, 36.1, 31.1, 24.0, 17.1 ppm, MS (ESI) calculated for $C_{22}H_{23}F_2NO_5$ $[M+Na]^+$ m/z : 442.41; found: 442.3.

4.4.5. (3*aS*,5*S*,9*aR*,10*aS*,10*bS*,*E*)-6,9*a*-Dimethyl-3-methylene-2-oxo-2,3,3*a*,4,5,8,9,9*a*,10*a*,10*b*-decahydrooxireno[2',3':9,10]cyclodeca[1,2-*b*]furan-5-yl (3,5-bis(trifluoromethyl)phenyl)carbamate (**8**)

Standard procedure was applied using 9(*S*)-hydroxy-parthenolide (**2**) (7.5 mg, 0.028 mmol), DBTDL (0.006 mmol), and substituted phenyl isocyanate (0.11 mmol). Isolated **PTL-09-33**: 11.1 mg, 75% yield. 1H NMR (500 MHz, $CDCl_3$): δ = 7.87 (s, 2H), 7.54 (s, 1H), 6.36 (d, J = 4.1 Hz, 1H), 5.69 (d, J = 4.1 Hz, 1H), 5.55 (dd, J = 3.4, 12.3 Hz, 1H), 5.22 (d, J = 11.1 Hz, 1H), 3.85 (t, J = 8.4 Hz, 1H), 2.96–2.89 (m, 1H), 2.69 (d, J = 9 Hz, 1H), 2.52–2.41 (m, 1H), 2.34–2.24 (m, 2H), 2.20–2.13 (m, 1H), 2.11–2.02 (m,

1H), 1.74 (s, 3H), 1.63–1.55 (m, 1H), 1.30 (s, 3H) ppm, ^{13}C NMR (125 MHz, $CDCl_3$): δ = 168.7, 159.4, 139.4, 139.3, 137.6, 132.4, 128.2, 122.5, 118.4, 117.1, 82.3, 81.4, 65.9, 61.3, 44.3, 36.3, 36.0, 23.8, 17.4, 11.9 ppm, MS (ESI) calculated for $C_{24}H_{23}F_6NO_5$ $[M+Na]^+$ m/z : 542.43; found: 542.5.

4.4.6. ((3*aR*,9*aR*,10*aS*,10*bS*,*Z*)-9*a*-Methyl-3-methylene-2-oxo-2,3,3*a*,4,5,8,9,9*a*,10*a*,10*b*-decahydrooxireno[2',3':9,10]cyclodeca[1,2-*b*]furan-6-yl)methyl (3,5-bis(trifluoromethyl)phenyl)carbamate (**9**)

Standard procedure was applied using 14-hydroxy-parthenolide (**3**) (5.6 mg, 0.021 mmol), DBTDL (0.004 mmol), and substituted phenyl isocyanate (0.030 mmol). Isolated **PTL-14-33**: 6.7 mg, 61% yield. 1H NMR (500 MHz, $CDCl_3$): δ = 7.90 (s, 2H), 7.76 (s, 1H), 7.51 (s, 1H), 6.27 (d, J = 3.5 Hz, 1H), 5.62 (d, J = 2.9 Hz, 1H), 5.49 (dd, J = 3.5, 12.2 Hz, 1H), 4.81 (d, J = 12.2 Hz, 1H), 4.75 (d, J = 12.2 Hz, 1H), 3.99 (t, J = 8.6, 1H), 2.84–2.78 (m, 1H), 2.75 (d, J = 8.8 Hz, 1H), 2.63–2.55 (m, 1H), 2.55–2.43 (m, 1H), 2.34–2.24 (m, 1H), 2.24–2.11 (m, 3H), 2.03–1.92 (m, 1H), 1.31 (s, 4H) ppm, ^{13}C NMR (125 MHz, $CDCl_3$): δ = 162.8, 153.1, 140.2, 139.7, 139.0, 132.9, 132.2, 122.3, 118.4, 116.6, 82.8, 66.1, 63.5, 63.2, 47.2, 36.3, 36.2, 24.2, 16.8 ppm, MS (ESI) calculated for $C_{24}H_{23}F_6NO_5$ $[M+Na]^+$ m/z : 542.43; found: 542.5.

4.4.7. (3*aS*,5*S*,9*aR*,10*aS*,10*bS*,*E*)-6,9*a*-Dimethyl-3-methylene-2-oxo-2,3,3*a*,4,5,8,9,9*a*,10*a*,10*b*-decahydrooxireno[2',3':9,10]cyclodeca[1,2-*b*]furan-5-yl naphthalen-1-ylcarbamate (**10**)

Standard procedure was applied using 9(*S*)-hydroxy-parthenolide (**2**) (8.0 mg, 0.030 mmol), DBTDL (0.006 mmol), and substituted phenyl isocyanate (0.012 mmol). Isolated **PTL-09-34**: 7.2 mg, 55% yield. 1H NMR (500 MHz, $CDCl_3$): δ = 7.88–7.81 (m, 2H), 7.69–7.63 (m, 1H), 7.54–7.42 (m, 3H), 6.96 (m, 1H), 6.34 (d, J = 4.0 Hz, 1H), 5.72 (d, J = 3.9 Hz, 1H), 5.51 (dd, J = 3.4, 11.8 Hz, 1H), 5.23 (d, J = 10.6 Hz, 1H), 3.83 (t, J = 8.7 Hz, 1H), 2.95–2.87 (m, 1H), 2.68 (d, J = 11.3 Hz, 1H), 2.52–2.40 (m, 1H), 2.36–2.28 (m, 2H), 2.28–2.21 (m, 1H), 2.18–2.12 (m, 1H), 2.01 (s, 3H), 1.65–1.51 (m, 1H), 1.29 (s, 3H) ppm, ^{13}C NMR (125 MHz, $CDCl_3$): δ = 168.9, 158.7, 146.6, 138.9, 135.0, 133.4, 133.1, 129.7, 128.7, 128.5, 127.8, 126.4, 126.1, 124.8, 121.2, 120.0, 82.7, 66.2, 61.4, 61.0, 47.1, 36.6, 36.0, 23.9, 17.2, 11.6 ppm, MS (ESI) calculated for $C_{26}H_{27}NO_5$ $[M+Na]^+$ m/z : 456.49; found: 456.5.

4.4.8. ((3*aR*,9*aR*,10*aS*,10*bS*,*Z*)-9*a*-Methyl-3-methylene-2-oxo-2,3,3*a*,4,5,8,9,9*a*,10*a*,10*b*-decahydrooxireno[2',3':9,10]cyclodeca[1,2-*b*]furan-6-yl)methyl naphthalen-1-ylcarbamate (**11**)

Standard procedure was applied using 14-hydroxy-parthenolide (**3**) (6 mg, 0.023 mmol), DBTDL (0.005 mmol), and substituted phenyl isocyanate (0.032 mmol). Isolated **PTL-14-34**: 8.4 mg, 85% yield. 1H NMR (500 MHz, $CDCl_3$): δ = 7.91–7.85 (m, 2H), 7.76–7.69 (m, 1H), 7.55–7.41 (m, 3H), 7.01 (m, 1H), 6.37 (d, J = 3.4 Hz, 1H), 5.70 (d, J = 3.3 Hz, 1H), 5.61 (dd, J = 3.5, 12.1 Hz, 1H), 4.87 (d, J = 12.5 Hz, 1H), 4.65 (d, J = 11.7 Hz, 1H), 3.95 (t, J = 8.5 Hz, 1H), 2.81–2.72 (m, 2H), 2.72–2.67 (m, 1H), 2.57–2.47 (m, 1H), 2.34–2.25 (m, 1H), 2.22–2.10 (m, 3H), 1.86–1.78 (m, 1H), 1.29–1.26 (m, 4H) ppm, ^{13}C NMR (125 MHz, $CDCl_3$): δ = 169.1, 157.9, 147.6, 139.2, 135.1, 133.7, 133.3, 129.7, 128.9, 128.6, 127.1, 126.3, 126.1, 124.9, 121.1, 120.0, 82.4, 66.3, 61.4, 61.2, 47.4, 36.8, 36.1, 23.9, 17.2 ppm, MS (ESI) calculated for $C_{26}H_{27}NO_5$ $[M+Na]^+$ m/z : 456.49; found: 456.4.

4.4.9. (3*aS*,5*S*,9*aR*,10*aS*,10*bS*,*E*)-6,9*a*-Dimethyl-3-methylene-2-oxo-2,3,3*a*,4,5,8,9,9*a*,10*a*,10*b*-decahydrooxireno[2',3':9,10]cyclodeca[1,2-*b*]furan-5-yl (4-nitrophenyl)carbamate (**12**)

Standard procedure was applied using 9(*S*)-hydroxy-parthenolide (**2**) (7.6 mg, 0.029 mmol), DBTDL (0.006 mmol), and substituted phenyl isocyanate (0.041 mmol). Isolated **PTL-09-35**: 4.3 mg, 35% yield. 1H NMR (500 MHz, $CDCl_3$): δ = 8.17 (d,

$J = 8.1$ Hz, 2H), 7.54 (d, $J = 9.3$ Hz, 2H), 6.33 (d, $J = 3.2$ Hz, 1H), 5.71 (d, $J = 3.1$ Hz, 1H), 5.51 (dd, $J = 4.1, 12.2$ Hz, 1H), 5.20 (d, $J = 10.4$ Hz, 1H), 3.81 (t, $J = 9.1$ Hz, 1H), 2.94–2.89 (m, 1H), 2.71 (d, $J = 10.1$ Hz, 1H), 2.58–2.49 (m, 1H), 2.35–2.22 (m, 2H), 2.19–2.13 (m, 1H), 2.04–1.98 (m, 1H), 1.74 (s, 3H), 1.65–1.52 (m, 1H), 1.20 (m, 3H) ppm, ^{13}C NMR (125 MHz, CDCl_3): $\delta = 164.4, 152.4, 144.9, 144.1, 138.1, 133.3, 127.1, 124.3, 121.1, 118.1, 83.1, 82.1, 66.1, 61.2, 44.3, 36.2, 36.1, 23.9, 17.0, 11.4$ ppm, MS (ESI) calculated for $\text{C}_{22}\text{H}_{24}\text{N}_2\text{O}_7$ $[\text{M}+\text{Na}]^+$ m/z : 451.43; found: 451.4.

4.4.10. ((3*aR*,9*aR*,10*aS*,10*bS*,*Z*)-9*a*-Methyl-3-methylene-2-oxo-2,3,3*a*,4,5,8,9*a*,10*a*,10*b*-decahydrooxireno[2',3':9,10]cyclodeca[1,2-*b*]furan-6-yl)methyl (4-nitrophenyl)carbamate (**13**)

Standard procedure was applied using 14-hydroxy-parthenolide (**3**) (5.8 mg, 0.022 mmol), DBTDL (0.004 mmol), and substituted phenyl isocyanate (0.031 mmol). Isolated **PTL-14-35**: 5.2 mg, 62% yield. ^1H NMR (500 MHz, CDCl_3): $\delta = 8.16$ (d, $J = 8.0$ Hz, 2H), 7.53 (d, $J = 9.5$ Hz, 2H), 6.29 (d, $J = 3.2$ Hz, 1H), 5.61 (d, $J = 3.2$ Hz, 1H), 5.51 (dd, $J = 4.4, 12.6$ Hz, 1H), 4.87 (d, $J = 12.0$ Hz, 1H), 4.71 (d, $J = 12.9$ Hz, 1H), 3.90 (t, $J = 9.3$ Hz, 1H), 2.84–2.78 (m, 1H), 2.75 (d, $J = 10.8$ Hz, 1H), 2.66–2.58 (m, 1H), 2.56–2.46 (m, 1H), 2.35–2.25 (m, 1H), 2.22–2.13 (m, 3H), 1.95–1.82 (m, 1H), 1.25–1.20 (m, 4H) ppm, ^{13}C NMR (125 MHz, CDCl_3): $\delta = 163.4, 152.3, 146.9, 144.8, 139.1, 133.3, 132.3, 125.3, 122.1, 118.0, 82.7, 66.1, 63.0, 61.3, 47.3, 36.9, 36.1, 31.6, 23.9, 16.9$ ppm, MS (ESI) calculated for $\text{C}_{22}\text{H}_{24}\text{N}_2\text{O}_7$ $[\text{M}+\text{Na}]^+$ m/z : 451.43; found: 451.4.

4.5. Synthesis of ester- and ether-based parthenologs

Compounds **14–35** were synthesized following our previously reported procedures^{26,27} at the 5–10 mg scale. The isolated yields were between 30% and 60% for the ester-based analogs and between 30 and 45% for the ether-based analogs.

4.6. X-ray crystallography

The structure of **14** was determined via single crystal X-ray diffraction analysis using a Bruker SMART APEX II CCD platform diffractometer. A detailed description of the procedures for X-ray diffraction data collection, analysis, and structure refinement are provided as Supporting Information and in Table S2. The crystal structure was deposited with the Cambridge Crystallographic Data Centre under the code CCDC 1546909.

4.7. Cell cultures

All cell lines were maintained in a 37 °C humidified incubator with 5% CO_2 . A549, MDA-MB-231, PC-3, SJS-1, SK-N-MC, HeLa, HCT-116 and SK-MEL-2 cells were cultured in DMEM medium (Gibco) supplemented with 10% FBS (Gibco) and 100 I.U./ml penicillin–streptomycin (Sigma). JeKo-1 and Jurkat cells were cultured in α -MEM medium (Gibco) supplemented with 10% FBS and 100 I. U./ml penicillin–streptomycin. Adherent cells were dissociated using Accutase (Millipore).

4.8. Cytotoxicity assay

Adherent cells were seeded in a 96-well plate at a density of 500–10,000 cells per well in 90 μl complete DMEM media. Suspension cells were seeded in conical 96-well plates (Nunc) at a density of 30,000 cells per well in 90 μl of complete α -MEM media devoid of phenol red indicator. The plates were incubated in a humidified incubator for 15 h prior to treatment. PTL analogs were prepared as concentrated stocks (10 mM) in DMSO and stored at -30 °C. Prior to testing, the analogs were diluted into complete cell culture med-

ium and the media was supplemented with sterile DMSO (10% of final volume). For the initial cytotoxicity screening, the compounds were added to the cells in 10 μl aliquots to give a final concentration of 10 μM parthenologs and 1% DMSO ($n = 5$). Following a 24-h incubation, the culture media from the adherent cell plates (e.g., HeLa, A549) was aspirated and replaced with 100 μl of 1mg/ml Thiazolyl Blue Tetrazolium Bromide (MTT, Sigma) in complete culture medium devoid of phenol red. For the suspension cells (Jurkat, JeKo-1), 20 μl of a 5 mg/ml Thiazolyl Blue Tetrazolium Bromide solution was added directly to the culture media. After incubation at 37 °C for 3 h, the plates were centrifuged (4000 rpm, 5 min), the media was removed and 100 μl of DMSO was added to solubilize the formazan product. The resulting OD was measured at 550 nm using a multi-well plate reader (Tecan).

Acknowledgments

The authors are grateful to Dr. Joshua N. Kolev and Dr. William Brennessel (U. Rochester) for assistance with crystallographic analyses. We thank Dr. Wei Hso (University of Rochester Medical Center, URMC) for the HCT-116 cell line, Dr. David Dean (URMC) for the A549 cell line, Dr. Ian Dickerson (URMC) for the SK-N-MC cell line, Dr. Vera Gorbunova for the PC-3 cell line and Dr. Andrew Terentis (Florida Atlantic University) for the HeLa, SK-MEL-2 and MDA-MB-231 cell lines. This work was supported by the Leukemia and Lymphoma Society Translational Research Grant LLS-6116-14 and in part by the U.S. National Institute of Health grant GM098628 awarded to R.F. B.J.F. acknowledges support from the National Institute of Health grant CA180615. MS instrumentation was supported by the U.S. National Science Foundation grant CHE-0946653.

A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmc.2017.08.009>.

References

- Breitmaier E. *Terpenes: Flavors, Fragrances, Pharmaca*. Weinheim: Phormones Wiley-VCH Verlag GmbH; 2006.
- Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N. *Drug Discov Today*. 2010;15:668.
- Ghantous A, Sinjab A, Hecceg Z, Darwiche N. *Drug Discov Today*. 2013;18:894.
- Guzman ML, Rossi RM, Karnischky L, et al. *Blood*. 2005;105:4163.
- Guzman ML, Jordan CT. *Expert Opin Biol Ther*. 2005;5:1147.
- An Y, Guo W, Li L, et al. *PLoS ONE*. 2015;10:e0116202.
- Hexum JK, Becker CM, Kempema AM, Ohlfest JR, Largaespada DA, Harki DA. *Bioorg Med Chem Lett*. 2015;25:2493.
- Janganati V, Ponder J, Jordan CT, Borrelli MJ, Penthalala NR, Crooks PA. *J Med Chem*. 2015;58:8896.
- Kempema AM, Widen JC, Hexum JK, et al. *Bioorg Med Chem*. 2015;23:4737.
- Nasim S, Pei S, Hagen FK, Jordan CT, Crooks PA. *Bioorg Med Chem*. 2011;19:1515.
- Srivastava SK, Abraham A, Bhat B, et al. *Bioorg Med Chem Lett*. 2006;16:4195.
- Zhang Q, Lu Y, Ding Y, et al. *J Med Chem*. 2012;55:8757.
- Garcia-Pineres AJ, Castro V, Mora G, et al. *J Biol Chem*. 2001;276:39713.
- Hehner SP, Heinrich M, Bork PM, et al. *J Biol Chem*. 1998;273:1288.
- Gopal YN, Chanchorn E, Van Dyke MW. *Mol Cancer Ther*. 2009;8:552.
- Pei S, Minhajuddin M, Callahan KP, et al. *J Biol Chem*. 2013;288:33542.
- Jung MS, Xuemin Q, Pramod U, Kwon HH, Fekadu K. *Curr Cancer Drug Targets*. 2014;14:59.
- Zhang S, Ong C-N, Shen H-M. *Cancer Lett*. 2004;211:175.
- Liu Z, Liu S, Xie Z, et al. *J Pharmacol Exp Ther*. 2009;329:505.
- Nakshatri H, Appaiah HN, Anjanappa M, et al. *Cell Death Dis*. 2015;6:e1608.
- Guzman ML, Rossi RM, Li XJ, et al. *Blood*. 2006;108:74a.
- Han C, Barrios FJ, Riofski MV, Colby DA. *J Org Chem*. 2009;74:7176.
- Nasim S, Crooks PA. *Bioorg Med Chem Lett*. 2008;18:3870.
- Neelakantan S, Nasim S, Guzman ML, Jordan CT, Crooks PA. *Bioorg Med Chem Lett*. 2009;19:4346.
- Woods JR, Mo H, Bieberich AA, Alavanja T, Colby DA. *J Med Chem*. 2011;54:7934.
- Kolev JN, O'Dwyer KM, Jordan CT, Fasan R. *ACS Chem Biol*. 2014;9:164.
- Tyagi V, Alwaseem H, O'Dwyer KM, et al. *Bioorg Med Chem*. 2016;24:3876.
- Ghosh AK, Brindisi M. *J Med Chem*. 2015;58:2895.

29. Vacondio F, Silva C, Mor M, Testa B. *Drug Metab Rev.* 2010;42:551.
30. Lam SW, Guchelaar HJ, Boven E. *Cancer Treat Rev.* 2016;50:9.
31. Brickner SJ, Barbachyn MR, Hutchinson DK, Manninen PR. *J Med Chem.* 2008;51:1981.
32. Ruane PJ, Brinson C, Ramgopal M, et al. *HIV Med.* 2015;16:288.
33. Sangal RB, Blumer JL, Lankford DA, Grinnell TA, Huang H. *Pediatrics.* 2014;134:e1095.
34. Narhi LO, Fulco AJ. *J Biol Chem.* 1987;262:6683.
35. Johannes TW, Woodyer RD, Zhao H. *Appl Environ Microbiol.* 2005;71:5728.
36. McLachlan MJ, Johannes TW, Zhao H. *Biotechnol Bioeng.* 2008;99:268.
37. Cui J, Hao J, Ulanovskaya OA, Dundas J, Liang J, Kozmin SA. *PNAS.* 2011;108:6763.
38. Labafzadeh SR, Kavakka JS, Vyavaharkar K, Sievanen K, Kilpelainen I. *RSC Adv.* 2014;4:22434.
39. Sweeney CJ, Mehrotra S, Sadaria MR, et al. *Mol Cancer Ther.* 2005;4:1004.
40. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. *Breast Cancer Res Treat.* 2008;111:419.
41. Kawasaki BT, Hurt EM, Kalathur M, et al. *Prostate.* 2009;69:827.
42. Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM. *Mol Cancer Ther.* 2005;4:587.
43. Kumar V, Kaur K, Gupta GK, Sharma AK. *Eur J Med Chem.* 2013;69:735.
44. Naim MJ, Alam O, Nawaz F, Alam MJ, Alam PJ. *Pharm Bioall Sci.* 2016;8:2.
45. Pei S, Minhajuddin M, D'Alessandro A, et al. *J Biol Chem.* 2016;291:25280.